Tja, da war wohl die Empörung sehr groß nach seinem ersten Artikel....
Link : www.thestreet.com/story/10662919/1/...cals.html?cm_ven=GOOGLEN
Link : www.thestreet.com/story/10662919/1/...cals.html?cm_ven=GOOGLEN
Top-News
Neuester,
zuletzt geles. Beitrag
Antworten | Hot-Stocks-Forum Übersicht
Zurück
Weiter
... 3 4 5 6 7 8 10 11
Antworten | Hot-Stocks-Forum Übersicht
Zurück
Weiter ... 3 4 5 6 7 8 10 11
Adventrx Pharmac. Heisses Eisen ?
Beiträge:
268
Zugriffe: 29.250 / Heute: 21
Zugriffe: 29.250 / Heute: 21
|
Werbung
Entdecke die beliebtesten ETFs von Amundi
Lyxor Net Zero 2050 S&P World Climate PAB (DR) UCITS ETF Acc
Perf. 12M: +206,18%
Amundi ETF Leveraged MSCI USA Daily UCITS ETF - EUR (C/D)
Perf. 12M: +81,87%
Amundi Nasdaq-100 Daily (2x) Leveraged UCITS ETF - Acc
Perf. 12M: +60,33%
Amundi MSCI Wld Clim. Paris Align. PAB Umw. UCITS ETF DR C/D
Perf. 12M: +39,03%
Amundi Russell 1000 Growth UCITS ETF - Acc
Perf. 12M: +38,69%
Posted by: bitty Date: Thursday, January 21, 2010 8:41:25 AM
In reply to: None Post # of 5577
This is Brian Culley's Response - so tomorrow's article should be very good for ANX!
I am doing my own article, but it won't be out until Monday. Here is the exact email from Brian Culley responding to Monday's Adam F.'s blog:
"Hi Traci,
Thanks for the link and for your interest in ADVENTRX. Interestingly, the highly-bearish A.F. valued us at our current market price with zero value ascribed to ANX-514 (or our cash)...effectively calling us a buy, but I do not expect it will be seen that way by his readers. I deeply respect A.F.'s right to hold and publish his opinions, and I welcome the scrutiny of informed analysts, but his two reports are filled with comments which reflect not only a different set of assumptions (e.g. he pulls a 2X premium for ANX-530 out of thin air), but moreover, a juvenile understanding of the basic workings of functional areas such as regulatory or commercialization. For example, he states that additional clinical data will be required in Europe. Unless he paid $60,000 to hold a scientific advice meeting with EMEA and discussed our data package with them, that's a wild-ass assumption which lies outside of our product profile (and one he makes despite my telling him about the EMEA hybrid application process). Or another example, he called our market research data "biased". The fact is, we commisioned a highly-respected, independent third-party to conduct an anonymous and robust conjoint analysis of 70 oncologists. We can't "unbias" it any more that that without avoiding the study altogether. And the market research firm's impeccable reputation is based on accuracy, not on feeding us big numbers (I don't want to hear big numbers if they are BS, I need the best estimate available to build a sustainable business). And although we think our strongest market penetration will be with community docs, we had both community and hospital docs polled - so we went out of our way to avoid a potential bias. Frankly, I could go on and on in painful detail on each and every point, but it's an inapropriate distraction for me to engage in a detailed dialog with every blogger. I do hope his readership (and our stockholders) will follow the company closely, educate themselves about the pharmaceutical industry, and come to independent decisions about their investments rather than follow the fleeting barks of outsiders. In the meantime, we will continue, as we have for years, and as virtually every other company does, to use conference presentations as a way to communicate and update our story to a wide audience, and if we become aware of certain issues arise that merit clarity, we incorporate those facts into our ever-evolving presentation. Stay in touch and thanks again for the link.
Best,
Brian"
This is Traci Hogg and I will be doing a follow up article. I personally believe that Adam F. has an agenda and that was to buy ANX much lower (after his articles did some damage.) This stock is a SCREAMING STRONG BUY!
In reply to: None Post # of 5577
This is Brian Culley's Response - so tomorrow's article should be very good for ANX!
I am doing my own article, but it won't be out until Monday. Here is the exact email from Brian Culley responding to Monday's Adam F.'s blog:
"Hi Traci,
Thanks for the link and for your interest in ADVENTRX. Interestingly, the highly-bearish A.F. valued us at our current market price with zero value ascribed to ANX-514 (or our cash)...effectively calling us a buy, but I do not expect it will be seen that way by his readers. I deeply respect A.F.'s right to hold and publish his opinions, and I welcome the scrutiny of informed analysts, but his two reports are filled with comments which reflect not only a different set of assumptions (e.g. he pulls a 2X premium for ANX-530 out of thin air), but moreover, a juvenile understanding of the basic workings of functional areas such as regulatory or commercialization. For example, he states that additional clinical data will be required in Europe. Unless he paid $60,000 to hold a scientific advice meeting with EMEA and discussed our data package with them, that's a wild-ass assumption which lies outside of our product profile (and one he makes despite my telling him about the EMEA hybrid application process). Or another example, he called our market research data "biased". The fact is, we commisioned a highly-respected, independent third-party to conduct an anonymous and robust conjoint analysis of 70 oncologists. We can't "unbias" it any more that that without avoiding the study altogether. And the market research firm's impeccable reputation is based on accuracy, not on feeding us big numbers (I don't want to hear big numbers if they are BS, I need the best estimate available to build a sustainable business). And although we think our strongest market penetration will be with community docs, we had both community and hospital docs polled - so we went out of our way to avoid a potential bias. Frankly, I could go on and on in painful detail on each and every point, but it's an inapropriate distraction for me to engage in a detailed dialog with every blogger. I do hope his readership (and our stockholders) will follow the company closely, educate themselves about the pharmaceutical industry, and come to independent decisions about their investments rather than follow the fleeting barks of outsiders. In the meantime, we will continue, as we have for years, and as virtually every other company does, to use conference presentations as a way to communicate and update our story to a wide audience, and if we become aware of certain issues arise that merit clarity, we incorporate those facts into our ever-evolving presentation. Stay in touch and thanks again for the link.
Best,
Brian"
This is Traci Hogg and I will be doing a follow up article. I personally believe that Adam F. has an agenda and that was to buy ANX much lower (after his articles did some damage.) This stock is a SCREAMING STRONG BUY!
Basher... Was ein Assi...Aber schön eins zwischen die Hörner hat er bekommen...
As promised, Adventrx Pharmaceuticals(ANX Quote) CEO Brian Culley wanted a chance to respond to my recent columns, which you can find here and here.
Brian, you're now steering the S.S. Mailbag: "Adam, thank you for the invitation to respond to your Biotech Stock Mailbag article of Jan. 19. Our company typically does not comment on analyst reports, blogs, etc., but there were two items in particular I felt required clarification. "First, you intimated that our ANX-530 market research data is biased. Our method for gathering market research is to conduct rigorous and anonymous analyses through respected third-party firms. This is done specifically to avoid making decisions based on optimistic or inadequate internal projections, which would serve neither us nor our investors. "Second, you cautioned your readers that Adventrx is 'running out of time' due to the introduction of generic forms of Taxotere. However, we know that all generic forms of Taxotere, as well as reformulations currently in patent litigation, contain polysorbate 80 (a detergent). Therefore, detergent-free ANX-514 is differentiated from both the branded drug (Taxotere) and its generic copies, regardless of when they may reach the market. We at Adventrx welcome scrutiny and we look forward to additional reports that may be published at TheStreet.com and other media channels."
Thanks, Brian, I'll take back the steering wheel now
www.thestreet.com/story/10665299/4/...tock-mailbag-genvec.html
Brian, you're now steering the S.S. Mailbag: "Adam, thank you for the invitation to respond to your Biotech Stock Mailbag article of Jan. 19. Our company typically does not comment on analyst reports, blogs, etc., but there were two items in particular I felt required clarification. "First, you intimated that our ANX-530 market research data is biased. Our method for gathering market research is to conduct rigorous and anonymous analyses through respected third-party firms. This is done specifically to avoid making decisions based on optimistic or inadequate internal projections, which would serve neither us nor our investors. "Second, you cautioned your readers that Adventrx is 'running out of time' due to the introduction of generic forms of Taxotere. However, we know that all generic forms of Taxotere, as well as reformulations currently in patent litigation, contain polysorbate 80 (a detergent). Therefore, detergent-free ANX-514 is differentiated from both the branded drug (Taxotere) and its generic copies, regardless of when they may reach the market. We at Adventrx welcome scrutiny and we look forward to additional reports that may be published at TheStreet.com and other media channels."
Thanks, Brian, I'll take back the steering wheel now
www.thestreet.com/story/10665299/4/...tock-mailbag-genvec.html
data.cnbc.com/quotes/ANX/tab/5.3
ih.advfn.com/...=A%5EANX&period=0&size=19&volume=1
ih.advfn.com/...=A%5EANX&period=0&size=19&volume=1
carpe diem
ich hab meine stücke äh auf long gehalten,daß wird noch richtig hoch gehn.
Scheinbar wird wieder auf ein Meetingtermin gezockt...
ADVENTRX Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference on February 9
Link: www.finanznachrichten.de/...r-conference-on-february-9-008.htm
ADVENTRX Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference on February 9
Link: www.finanznachrichten.de/...r-conference-on-february-9-008.htm
ADVENTRX Appoints Icahn Representative to Board of Directors
Date : 02/03/2010 @ 8:00AM
Source : PR Newswire
Stock : (ANX)
Quote : 0.32 0.0 (0.00%) @ 8:36AM
ADVENTRX Appoints Icahn Representative to Board of Directors
SAN DIEGO, Feb. 3 /PRNewswire-FirstCall/ --
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that Odysseas D. Kostas, M.D. will join its Board of Directors. Dr. Kostas also will serve on the Board's Audit Committee. Dr. Kostas was appointed as the representative of entities affiliated with Carl C. Icahn
"We are delighted to welcome Odysseas to our Board of Directors," said Jack Lief, Chair of the ADVENTRX Board of Directors and the Board's Audit Committee. "His insights should prove valuable as we advance our product candidates towards commercialization."
Dr. Kostas, M.D. is an attending physician and one of seven hospitalists at Greenwich Hospital, a member of the Yale New Haven Health System and a subsidiary of Greenwich Health Care Services, Inc. At Greenwich Hospital, Dr. Kostas is a member of various committees that oversee aspects of the hospital's operational decision-making. Since March 2007, Dr. Kostas has provided advisory services to Boards of Directors of biotechnology companies, primarily in the area of strategic and partnering transactions, including ImClone Systems Incorporated prior to its sale to Eli Lilly and Company. In May 2003, Dr. Kostas founded a private medical practice that he owned and operated, treating over 2,000 patients, until May 2008. Dr. Kostas holds a B.S. in biology from the Massachusetts Institute of Technology and an M.D. from the University of Texas Southwestern Medical School and is board certified in internal medicine
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. More information can be found on ADVENTRX's web site at www.adventrx.com/
Forward Looking Statements
ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: successfully educating new directors and integrating new directors with existing directors and management; the risk that directors' will undertake projects that divert their respective attention from ADVENTRX matters, or that may pose a conflict of interest with ADVENTRX; ADVENTRX's dependence on the success of ANX-530, and uncertainty as to whether ANX-530 will receive regulatory approval or be commercialized successfully; the potential that FDA may not accept the ANX-530 NDA for review, or that the bioequivalence data and other information included in the ANX-530 NDA may not adequately support bioequivalence with Navelbine, including as a result of performing pharmacokinetic equivalence analyses based on a patient population other than the population on which ADVENTRX based its analysis; the potential that changes made in transferring the manufacturing process for ANX-530 may result in a lack of comparability between the commercial product and the material used in clinical trials, and that FDA may require ADVENTRX to perform additional non-clinical or clinical studies; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at www.sec.gov/
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date on which it was made.
DATASOURCE: ADVENTRX Pharmaceuticals, Inc
CONTACT: Brian Culley, Principal Executive Officer of ADVENTRX
Pharmaceuticals, +1-858-552-0866; or Investors, Don Markley of
Lippert/Heilshorn & Associates, Inc., +1-310-691-7100, , for
ADVENTRX Pharmaceuticals
Web Site: www.adventrx.com/
ih.advfn.com/...204188&article=41377424&symbol=A%5EANX
Date : 02/03/2010 @ 8:00AM
Source : PR Newswire
Stock : (ANX)
Quote : 0.32 0.0 (0.00%) @ 8:36AM
ADVENTRX Appoints Icahn Representative to Board of Directors
SAN DIEGO, Feb. 3 /PRNewswire-FirstCall/ --
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that Odysseas D. Kostas, M.D. will join its Board of Directors. Dr. Kostas also will serve on the Board's Audit Committee. Dr. Kostas was appointed as the representative of entities affiliated with Carl C. Icahn
"We are delighted to welcome Odysseas to our Board of Directors," said Jack Lief, Chair of the ADVENTRX Board of Directors and the Board's Audit Committee. "His insights should prove valuable as we advance our product candidates towards commercialization."
Dr. Kostas, M.D. is an attending physician and one of seven hospitalists at Greenwich Hospital, a member of the Yale New Haven Health System and a subsidiary of Greenwich Health Care Services, Inc. At Greenwich Hospital, Dr. Kostas is a member of various committees that oversee aspects of the hospital's operational decision-making. Since March 2007, Dr. Kostas has provided advisory services to Boards of Directors of biotechnology companies, primarily in the area of strategic and partnering transactions, including ImClone Systems Incorporated prior to its sale to Eli Lilly and Company. In May 2003, Dr. Kostas founded a private medical practice that he owned and operated, treating over 2,000 patients, until May 2008. Dr. Kostas holds a B.S. in biology from the Massachusetts Institute of Technology and an M.D. from the University of Texas Southwestern Medical School and is board certified in internal medicine
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. More information can be found on ADVENTRX's web site at www.adventrx.com/
Forward Looking Statements
ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: successfully educating new directors and integrating new directors with existing directors and management; the risk that directors' will undertake projects that divert their respective attention from ADVENTRX matters, or that may pose a conflict of interest with ADVENTRX; ADVENTRX's dependence on the success of ANX-530, and uncertainty as to whether ANX-530 will receive regulatory approval or be commercialized successfully; the potential that FDA may not accept the ANX-530 NDA for review, or that the bioequivalence data and other information included in the ANX-530 NDA may not adequately support bioequivalence with Navelbine, including as a result of performing pharmacokinetic equivalence analyses based on a patient population other than the population on which ADVENTRX based its analysis; the potential that changes made in transferring the manufacturing process for ANX-530 may result in a lack of comparability between the commercial product and the material used in clinical trials, and that FDA may require ADVENTRX to perform additional non-clinical or clinical studies; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at www.sec.gov/
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date on which it was made.
DATASOURCE: ADVENTRX Pharmaceuticals, Inc
CONTACT: Brian Culley, Principal Executive Officer of ADVENTRX
Pharmaceuticals, +1-858-552-0866; or Investors, Don Markley of
Lippert/Heilshorn & Associates, Inc., +1-310-691-7100, , for
ADVENTRX Pharmaceuticals
Web Site: www.adventrx.com/
ih.advfn.com/...204188&article=41377424&symbol=A%5EANX
und keiner da der sich freut :-(
finde keine News habt ihr was?
finde keine News habt ihr was?
pennystockgurus.blogspot.com/2010/02/...ush-above-52-week.html
wie im lotto alles ist möglich!
kaufe aktien die keiner mehr haben will
und am ende wird alles gut!
kaufe aktien die keiner mehr haben will
und am ende wird alles gut!
ANX / Posted by: zigzagman Date: Sunday, February 21, 2010 1:33:24 PM
In reply to: None Post # of 6677
VIDEO: Technical Analysis of the Daily & Weekly Charts:
I am using a new service to upload my videos to because YouTube limits you to only ten minutes of play time for each video, and that is not enough time to express everything I want to...
The video I made today is thirty-five minutes long, and is best viewed in Full Screen Mode...To go to Full Screen Mode, click on the button in the lower right hand corner that has four arrows pointing in different directions...Press the Escape key on your keyboard to exit Full Screen Mode...
Here is a link to the Viddler.com site that stores my longer videos:
www.viddler.com/explore/zigzagman/videos/5/
I hope you enjoy this Fundamental and Technical Analysis on ANX, and remember that all comments made on this video are all in my opinion only...
Happy Trading,
zigzagman
In reply to: None Post # of 6677
VIDEO: Technical Analysis of the Daily & Weekly Charts:
I am using a new service to upload my videos to because YouTube limits you to only ten minutes of play time for each video, and that is not enough time to express everything I want to...
The video I made today is thirty-five minutes long, and is best viewed in Full Screen Mode...To go to Full Screen Mode, click on the button in the lower right hand corner that has four arrows pointing in different directions...Press the Escape key on your keyboard to exit Full Screen Mode...
Here is a link to the Viddler.com site that stores my longer videos:
www.viddler.com/explore/zigzagman/videos/5/
I hope you enjoy this Fundamental and Technical Analysis on ANX, and remember that all comments made on this video are all in my opinion only...
Happy Trading,
zigzagman
Das wird ein tiefroter Tag heute...Der Novelos zieht seine Kreise....
FDA verlangt zusätzliche Daten...In meinen Augen ganz normales Business. Naja. Mal den PreMarket abwarten wohin die Reise geht.
Link: www.finanznachrichten.de/...entrx-pharmaceuticals.asp#16254759
FDA verlangt zusätzliche Daten...In meinen Augen ganz normales Business. Naja. Mal den PreMarket abwarten wohin die Reise geht.
Link: www.finanznachrichten.de/...entrx-pharmaceuticals.asp#16254759
für Dein Posting.Hab direkt verkauft,den Rest kannst Du Dir denken.Einige MM gehören hinter Gitter.
Das Geld gleicht dem Seewasser,jemehr man davon trinkt,umso durstiger wird man.
es pendelt sich schon wieder ein.
einige lernen es nie,sofort mit riesen verlust zu verkaufen.
entweder man verkauft sofort oder man sitzt es aus mit nachkäufen.
nur meine meinung,hab nachgekauft.
einige lernen es nie,sofort mit riesen verlust zu verkaufen.
entweder man verkauft sofort oder man sitzt es aus mit nachkäufen.
nur meine meinung,hab nachgekauft.
Da gehören wirklich so einige MM´s ins Kaffee Viereck gesteckt...Die News hat keine Relevanz zum Medikament selber, aber es wird so gehandelt als ob die FDA das Medikament hat durchfallen lassen...
Alle die sich rauskicken lassen haben, mein Beileid...
Alle die sich rauskicken lassen haben, mein Beileid...
oder man hat wider jede Vernunft ausnahmsweise mal einen SL gesetzt,der natürlich erst am Boden greift.
Kann man heute schön verfolgen.Haben die MM's wohl mal wieder gewürfelt.
Biotecs sind z.Z.wirklich nicht leicht zu handeln.Bei pos.News z.B.Labopharm gehts genauso runter,wie bei
neg.News z.B.Novelos,ADVFN.etc.
Werd mich jetzt wieder meiner Human widmen( Kauf bei 1,20€ ),da geht eher noch was,als bei diesen Harakiri
Werten.
Grüße an alle Investierten.
Kann man heute schön verfolgen.Haben die MM's wohl mal wieder gewürfelt.
Biotecs sind z.Z.wirklich nicht leicht zu handeln.Bei pos.News z.B.Labopharm gehts genauso runter,wie bei
neg.News z.B.Novelos,ADVFN.etc.
Werd mich jetzt wieder meiner Human widmen( Kauf bei 1,20€ ),da geht eher noch was,als bei diesen Harakiri
Werten.
Grüße an alle Investierten.
Das Geld gleicht dem Seewasser,jemehr man davon trinkt,umso durstiger wird man.
mal schaun was nach 16 uhr passiert.
hab heute keine news gefunden.
hab heute keine news gefunden.
kann mir recht sein,bin investiert und voll überzeugt
das es noch richtig hoch gehen wird in diesem monat.
hop hop mach mal größere sprünge,hahaha
das es noch richtig hoch gehen wird in diesem monat.
hop hop mach mal größere sprünge,hahaha
gesetzt,mal sehen,scheint mir interessant zu sein.
Es gibt keine neuen Beiträge.
|
Neueste Beiträge aus dem Savara Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
2 | 90 | Mast Therapeuthicals MSTX - Buy | Barica Investments | logall | 18:42 | |
| 9 | 267 | Adventrx Pharmac. Heisses Eisen ? | plusquamperfekt | wes_ | 13.09.11 17:20 | |
| 1 | watchlist bei pennystocklive | ARTNER514 | alice.im.börsenland | 10.06.10 15:40 |
